Featured Research

from universities, journals, and other organizations

Arteries Secretly Re-Clog After Angioplasty More Than Half The Time

Date:
November 7, 2001
Source:
American Heart Association
Summary:
More than half of patients whose heart arteries re-narrow after angioplasty, a procedure to open clogged blood vessels, may have no symptoms of their renewed disease, researchers report in Circulation: Journal of the American Heart Association.

DALLAS, Nov. 6 – More than half of patients whose heart arteries re-narrow after angioplasty, a procedure to open clogged blood vessels, may have no symptoms of their renewed disease, researchers report in today’s Circulation: Journal of the American Heart Association.

“These patients may have a silent risk of future coronary events, such as a heart attack,” says lead author Peter N. Ruygrok, M.B.Ch.B., consultant cardiologist at Green Lane Hospital in Auckland, New Zealand. “Yet, they believe they have had a successful treatment for their obstructive artery narrowing.”

The study also identified three factors that seem to influence whether patients are more likely to develop symptomless, or “silent,” heart disease within six months after treatment. These factors are gender, the severity of the blockage at a six-month follow-up angiography, and the artery’s reference diameter (the diameter just before and just after the fatty obstruction).

Men were more likely than women to have silent restenosis (the re-narrowing of arteries after they are unclogged). The researchers suggest that the gender difference could be explained by the fact that women have smaller artery diameters. Other factors may also play a role, they add, citing that several studies have documented gender differences in treatment of patients with coronary heart disease, and that the initial diagnosis of angina is made later in women than in men.

Patients with less severe blockage and those whose arteries had a wider reference diameter were also more likely to have silent restenosis. For their study, the researchers defined restenosis as a 50 percent or greater narrowing of an artery. Of the 2,690 patients, 607 had a blockage of 50 percent or more in their treated arteries six months after their procedure. Of those with restenosis, 335 patients (55 percent) had no symptoms.

“We wondered whether there might be a subgroup of patients who should be targeted to have routine six-month angiograms following coronary-artery intervention,” Ruygrok says.

To answer that question, they compared 46 factors to see if any significant differences existed between patients with symptoms and those with silent heart disease. These factors included age, gender, smoking history, heart medication use, and certain physical characteristics of the heart artery.

“We were surprised that there were not more predictive factors, such as diabetes,” says Ruygrok, who is also an honorary senior lecturer at the University of Auckland.

“Even though these new data would not necessarily make us alter clinical practice – such as performing a routine, six-month angiography following coronary intervention – these three factors may raise our level of suspicion about patients in whom the clinical diagnosis is not clear-cut,” he says.

Restenosis occurs in 10 percent to 40 percent of patients, according to various studies. Previous research has indicated that a significant number of patients who develop restenosis do so without symptoms, particularly chest pain known as angina.

“This occurred in 55 percent of those with restenosis in our study, which in itself is an interesting finding,” says Ruygrok. “These people remain well, but with a potentially significant coronary problem.”

For their study, he and his colleagues combined and analyzed the records of 2,690 patients treated in 10 studies for obstructed heart arteries. The patients either had balloon angioplasty or insertion of a stent – a flexible, mesh tube used to help keep arteries open. All of these procedures are nonsurgical but require threading a catheter into a heart artery narrowed by fatty deposits to restore blood flow to the heart muscle.

In addition to an artery-opening procedure, each patient also had an angiographic examination of their heart arteries six months after their treatment. “Angiography, which is not the usual clinical practice after these interventions, is the only definite way to identify silent restenosis,” Ruygrok notes.

Co-authors were Mark W. I. Webster, M.B.Ch.B.; Vincent de Valk, Ph.D.; Gerrit-Anne van Es, Ph.D.; John A. Ormiston, M.B.Ch.B.; Marie-Angθle M. Morel, B.Sc.; and Patrick W. Serruys, M.D., Ph.D.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Arteries Secretly Re-Clog After Angioplasty More Than Half The Time." ScienceDaily. ScienceDaily, 7 November 2001. <www.sciencedaily.com/releases/2001/11/011106084248.htm>.
American Heart Association. (2001, November 7). Arteries Secretly Re-Clog After Angioplasty More Than Half The Time. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2001/11/011106084248.htm
American Heart Association. "Arteries Secretly Re-Clog After Angioplasty More Than Half The Time." ScienceDaily. www.sciencedaily.com/releases/2001/11/011106084248.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins